Insys Therapeutics (INSY) 10-K 3 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Feb. 26, 2015	Jun. 30, 2014
Entity Registrant Name	Insys Therapeutics, Inc.
Entity Central Index Key	1516479
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		35,459,644
Entity Public Float			$318.40
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and Cash Equivalents	$58,106,000	$45,382,000
Restricted cash		400,000
Short-term Investments	24,757,000
Accounts receivable, net of allowances of $5,816 and $2,748 at December 31, 2014 and 2013, respectively	26,544,000	16,313,000
Inventories	34,781,000	14,528,000
Prepaid expenses and other assets	2,243,000	1,727,000
Deferred income tax assets	4,611,000	3,800,000
Total current assets	151,042,000	82,150,000
Total fixed assets	29,872,000	10,127,000
Long-term Investments	23,262,000
Deferred income tax assets	7,602,000	8,238,000
Other assets	3,343,000	43,000
Total assets	215,121,000	100,558,000
Current Liabilities:
Accounts payable and accrued expenses	27,454,000	12,173,000
Accrued compensation	6,926,000	3,568,000
Accrued sales allowances	11,296,000	5,340,000
Total current liabilities	45,676,000	21,081,000
Uncertain income tax position	3,778,000
Total liabilities	49,454,000	21,081,000
Commitments and contingencies
Stockholders' Equity:
Preferred stock (par value $0.001 per share, 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2014 and 2013, respectively)	0	0
Common stock (par value $0.01 per share; 100,000,000 and 50,000,000 shares authorized as of December 31, 2014 and 2013, respectively; 35,351,344 and 33,184,892 shares issued and outstanding as of December 31, 2014 and 2013, respectively)	354,000	332,000
Additional paid in capital	216,414,000	168,199,000
Unrealized loss on available-for-sale securities	-24,000
Notes receivable from stockholders	-21,000	-21,000
Accumulated deficit	-51,056,000	-89,033,000
Total stockholders' equity	165,667,000	79,477,000
Total liabilities and stockholders' equity	$215,121,000	$100,558,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowance for doubtful accounts	$5,816	$2,748
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	100,000,000	50,000,000
Common stock, shares issued (in shares)	35,351,344	33,184,892
Common stock, shares outstanding (in shares)	35,351,344	33,184,892

Consolidated_Statements_of_Inc

Consolidated Statements of Income and Comprehensive Income (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net revenue	$222,125	$99,289
Cost of revenue	22,578	12,665
Gross profit	199,547	86,624
Operating expenses:
Sales and marketing	58,105	29,194
Research and development	33,136	8,499
General and administrative	44,283	16,372
Total operating expenses	135,524	54,065
Operating income	64,023	32,559
Other income (expense):
Interest income	151	22
Interest expense		-950
Other income (expense), net	2	-54
Total other income (expense)	153	-982
Income before income taxes	64,176	31,577
Income tax (expense) benefit	-26,199	8,800
Net income	37,977	40,377
Unrealized loss on available-for-sale securities	-24
Total comprehensive income	$37,953	$40,377
Earnings Per Share [Abstract]
Basic (in dollars per share)	$1.10	$1.56
Diluted (in dollars per share)	$1.04	$1.41
Weighted average common shares outstanding
Weighted average number of common shares outstanding (in shares)	34,379,535	25,919,768
Diluted (in shares)	36,667,566	28,734,617

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Accumulated Net Unrealized Investment Gain (Loss) [Member]	Additional Paid-in Capital [Member]	Common Stock [Member]	Convertible Preferred Stock [Member]	Receivables from Stockholder [Member]	Retained Earnings [Member]
In Thousands, except Share data
Balance at Dec. 31, 2012	($64,827)		$64,591	$13	$149	($21)	($129,410)
Balance (in shares) at Dec. 31, 2012				1,284,059	14,864,607
Conversion of preferred to common stock (in shares)				12,793,290	-14,864,607
Conversion of preferred to common stock	149		21	128	-149
Conversion of notes payable to common stock (in shares)				11,115,512
Conversion of notes payable to common stock	59,284		59,173	111
Issuance of common stock - initial public offering (in shares)				6,900,000
Issuance of common stock - initial public offering	32,456		32,387	69
Issuance of common stock - employee stock purchase plan (in shares)				188,055
Issuance of common stock - employee stock purchase plan	852		850	2
Exercise of stock options (in shares)	903,977			903,977
Exercise of stock options	2,102		2,093	9
Excess tax benefits on stock options and awards	2,745		2,745
Stock based compensation - stock options and awards	6,339		6,339
Net income (loss)	40,377						40,377
Balance at Dec. 31, 2013	79,477		168,199	332		-21	-89,033
Balance (in shares) at Dec. 31, 2013				33,184,892
Issuance of common stock - employee stock purchase plan (in shares)				358,057
Issuance of common stock - employee stock purchase plan	1,989		1,985	4
Exercise of stock options (in shares)	1,808,395			1,808,395
Exercise of stock options	8,956		8,938	18
Excess tax benefits on stock options and awards	22,003		22,003
Stock based compensation - stock options and awards	15,289		15,289
Net income (loss)	37,977						37,977
Unrealized loss on available-for-sale securities	-24	-24
Balance at Dec. 31, 2014	$165,667	($24)	$216,414	$354		($21)	($51,056)
Balance (in shares) at Dec. 31, 2014				35,351,344

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent	$37,977,000	$40,377,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,500,000	1,788,000
Stock-based compensation	15,289,000	6,339,000
Deferred income tax benefit	-175,000	-12,038,000
Excess tax benefits on stock options and awards	-22,003,000	-2,745,000
Interest expense accrued on notes payable		900,000
Changes in operating assets and liabilities:
Accounts receivable	-10,230,000	-13,224,000
Inventories	-20,253,000	-7,433,000
Prepaid expenses and other current assets	-3,816,000	-365,000
Accounts payable, accrued expenses and other current liabilities	50,375,000	10,650,000
Net cash provided by operating activities	49,664,000	24,249,000
Cash flows from investing activities:
Change in restricted cash and restricted cash equivalents	400,000	-400,000
Purchase of investments	-48,043,000
Purchases of property and equipment	-22,245,000	-5,125,000
Net cash used in investing activities	-69,888,000	-5,525,000
Cash flows from financing activities:
Proceeds from issuance of common stock	1,989,000	33,308,000
Net repayments on line of credit		-11,858,000
Excess tax benefits on stock options and awards	22,003,000	2,745,000
Proceeds from exercise of stock options	8,956,000	2,102,000
Net cash provided by financing activities	32,948,000	26,297,000
Change in cash and cash equivalents	12,724,000	45,021,000
Cash and cash equivalents, beginning of year	45,382,000	361,000
Cash and cash equivalents, end of year	58,106,000	45,382,000
Supplemental cash flow disclosures:
Cash paid for interest expense		51,000
Cash paid for income taxes	$2,975,000	$991,000

Note_1_Nature_of_Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1.        Nature of Business
	Insys Therapeutics, Inc., which was incorporated in Delaware in June 1990, and our subsidiaries (collectively, “we,” “us,” and “our”) maintain headquarters in Chandler, Arizona.
	We are a specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products: Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in patients with AIDS.

Note_2_Significant_Accounting_

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2.        Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of Insys Therapeutics, Inc. and its wholly-owned subsidiary, Insys Pharma, Inc. (“Insys Pharma”). All significant intercompany balances and transactions have been eliminated in the accompanying consolidated financial statements.
	Reclassification
	Certain amounts in the 2013 consolidated financial statements have been reclassified to conform to the 2014 presentation.
	Fair Value of Financial Instruments
	The carrying values of our financial instruments, including cash, accounts receivable and accounts payable approximate their fair value due to the short term nature of these financial instruments.
	Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 820, “Fair Value Measurement” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	Revenue Recognition
	We recognize revenue from the sale of Subsys and Dronabinol SG Capsule. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.
	Subsys
	Subsys was commercially launched in March 2012, and is available through a U.S. Food and Drug Administration (“FDA”) mandated Risk Evaluation and Mitigation program known as the Transmucosal Immediate Release Fentanyl program (“TIRF REMS”). We sell Subsys in the United States to wholesale pharmaceutical distributors, and on a very limited basis directly to retail pharmacies, or collectively our customers, on a wholesale basis, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. Subsys currently has a shelf life of 36 months from the date of manufacture. Given the limited sales history of prescriptions of Subsys prior to the fourth quarter of 2013, we were not able to reliably estimate expected returns of the product at the time of shipment prior to the fourth quarter of 2013. Accordingly, we initially deferred the recognition of revenue and related product costs of Subsys product shipments until the product was dispensed through patient prescriptions. The quantity of prescription units dispensed was estimated using an analysis of third-party information, including TIRF REMS mandated data and third-party market research data. Beginning in the fourth quarter of 2013, we were able to reasonably estimate product returns of Subsys. Therefore, we began recognizing revenue for Subsys sales at the time of shipment. Accordingly, in the fourth quarter of 2013, we recognized a one-time increase of $1.5 million in net product sales of Subsys, representing product sales previously deferred, net of estimated product returns, wholesaler discounts, prompt pay discounts, stocking allowances, patient discount programs, rebates, and chargebacks. Including deferred cost of sales, this change resulted in a one-time $0.9 million increase to operating income for the year ended December 31, 2013.
	We recognize estimated product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future discounts taken. In certain cases, such as patient assistance programs, we recognize the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, we may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Our product sales allowances include:
	Product Returns.
	We allow customers to return product for credit within six months before and up to 12 months following its product expiration date. The shelf life of Subsys is currently 36 months from the date of manufacture. We have monitored actual return history since product launch, which provides us with a basis to reasonably estimate future product returns, taking into consideration the shelf life of product at the time of shipment, shipment and prescription trends, estimated distribution channel inventory levels, and consideration of the introduction of competitive products.
	Because of the shelf life of our products and our return policy of issuing credits on returned product that is within six months before and up to 12 months after its product expiration date, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. Accordingly, we may have to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustments. The allowance for product returns is included in sales allowances.
	Wholesaler Discounts
	.    We offer discounts to certain wholesale distributors based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognize the discount as a reduction of revenue in the same period the related revenue is recognized.
	Prompt Pay Discounts
	.    We offer cash discounts to our customers, generally 2.0% of the sales price, as an incentive for prompt payment. We account for cash discounts by reducing accounts receivable by the full amount and recognize the discount as a reduction of revenue in the same period the related revenue is recognized.
	Stocking Allowances
	.    We may offer discounts and extended payment terms, generally in the month of the initial commercial launch of a new product and on the first order made by certain wholesale distributors and retail pharmacies based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognize the discount as a reduction of revenue in the same period the related revenue is recognized.
	Patient Discount Programs
	.    We offer discount card programs to patients for Subsys in which patients receive discounts on their prescriptions that are reimbursed by us to the retailer. We estimate the total amount that will be redeemed based on a percentage of actual redemption applied to inventory in the distribution and retail channel and recognize the discount as a reduction of revenue in the same period the related revenue is recognized. The allowance for patient discount programs is included in accrued sales allowances.
	Rebates
	.    We participate in certain rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, we pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. We estimate and accrue these rebates based on current contract prices, historical and estimated future percentages of products sold to qualified patients and estimated levels of inventory in the distribution channel. Rebates are recognized as a reduction of revenue in the period the related revenue is recognized. The allowance for rebates is included in accrued sales allowances.
	Chargebacks.
	We provide discounts primarily to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the entity paid for the product. We estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. The allowance for chargebacks is included as a reduction to accounts receivable.
	Dronabinol SG Capsule
	Dronabinol SG Capsule was commercially launched in December 2011, and we sell Dronabinol SG Capsule exclusively to Mylan Pharmaceuticals, Inc. (“Mylan”) in the United States under a supply and distribution agreement. Pursuant to the terms of the Mylan agreement, we manufacture Dronabinol SG Capsule under the Mylan label. Mylan distributes Dronabinol SG Capsule and on a monthly basis pays us an amount equal to the value of Dronabinol SG Capsule it sold to wholesale pharmaceutical distributors, less contractually defined deductions for chargebacks, rebates, sales discounts, distribution and storage fees, and royalties. Under the terms of the supply and distribution agreement with Mylan, we are obligated to pay Mylan a royalty of between 10% and 20% on Mylan’s net product sales, and a single digit percentage fee on such sales for distribution and storage services. We bear no risk of product return upon acceptance by Mylan. As Mylan has control over the amount it charges to wholesale pharmaceutical distributors for Dronabinol SG Capsule and the discounts offered to the distributors, the sales price is not fixed and determinable at the date we ship such products to Mylan. Accordingly, we recognize revenue upon Mylan’s sale of products to wholesale distributors, which is the point at which the sales price is fixed and determinable. See Note 8 under the heading “-Legal Matters” of these Notes for a discussion on our ongoing dispute with Mylan.
	Cash and Cash Equivalents
	We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which at times may exceed FDIC limits.
	Accounts Receivable, Net
	Trade accounts receivable are recorded at the invoice amount net of allowances for wholesaler discounts, prompt pay discounts, stocking allowances, and doubtful accounts. See Note 2 – “Revenue Recognition” above for a description of our wholesaler discounts, prompt pay discounts, stocking allowances and chargebacks. We evaluate the collectability of our accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience.
	Inventories
	Inventories consist of raw materials, work-in-process and finished product and are valued at the lower of cost (first-in, first-out cost method) or market. Inventory costs are capitalized prior to regulatory approval and product launch based on management’s judgment of probable future commercial use and net realizable value of the inventory. Such judgment incorporates our knowledge and best estimate of where the relevant product is in the regulatory process, our required investment in the product, market conditions, competing products and our economic expectations for the product post-approval relative to the risk of manufacturing the product prior to approval. In evaluating the recoverability of inventories produced in preparation for product launches, we consider the probability that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process, as well as the market for the product in its current state. We could be required to permanently write down previously capitalized costs related to pre-approval or pre-launch inventory upon a change in such judgment, due to a denial or delay of approval by regulatory bodies, a delay in commercialization, or other potential factors including product expiration.
	Property and Equipment
	Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.
	Income Taxes
	We account for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the “NOLs”) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date.
	We record a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations.
	We recognize a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.
	Our policy is to classify interest and penalties associated with income tax liabilities as income tax expense in the statement of operations.
	Research and Development Expenses
	Research and development (“R&D”) costs are expensed when incurred. These costs consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.
	Advertising and Marketing
	Advertising and marketing costs are expensed as incurred.
	Stock-Based Compensation Expenses
	Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options using the following assumptions:
		●	Exercise price - Prior to May 7, 2013, we determined the exercise price based on valuations using the best information available to management at the time of the valuations. Subsequent to our initial public offering of common stock (“IPO”) on May 7, 2013, the exercise price is equal to the fair market value of the stock on the grant date which is determined based on quoted market prices.
		●	Volatility - Prior to our IPO, we did not have a reliable history of market prices for our common stock. Following our IPO, while we have an active trading market, we do not have sufficient historical data to accurately determine volatility for the period equivalent to the expected term of the stock option grants. Accordingly, we estimate the expected stock price volatility for our common stock by taking the median historical stock price volatility for industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants.
		●	Expected term - The expected term is based on a simplified method which defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards.
		●	Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted.
		●	Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.
		●	Forfeitures - Forfeitures have historically been insignificant.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could materially differ from those estimates.
	Segment Information
	FASB ASC No. 280, “Segment Reporting” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (“CODM”), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on our integration and management strategies, we operate in a single reportable segment.
	Recent Accounting Pronouncements
In May 2014, the FASB issued Accounting Standards Update No. 2014-09,
Revenue from Contracts with Customers
(ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017.

Note_3_Shortterm_and_Longterm_

Note 3 - Short-term and Long-term Investments	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Investment [Text Block]	3	Short-Term and Long-Term Investments
	Our policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to our investment guidelines and market conditions. Short-term and long-term investments consist of corporate, various government agency and municipal debt securities, as well as certificates of deposit that have maturity dates that are greater than 90 days. Certificates of deposit are carried at cost which approximates fair value. We classify our marketable securities as available-for-sale in accordance with FASB Accounting Standards Codification Topic 320,
	Investments — Debt and Equity Securities
	. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in stockholders’ equity. A decline in the market value of any available-for-sale security below cost that is deemed to be other than temporary, results in impairment of the fair value of the investment. We did not have any realized gains or losses or decline in values judged to be other than temporary during the year ended December 31, 2014. If we had realized gains and losses and declines in value judged to be other than temporary, we would have been required to include those changes in other expense in the consolidated statements of income and comprehensive income. Premiums and discounts are amortized or accreted over the life of the related available-for-sale security. The cost of securities sold is calculated using the specific identification method. At December 31, 2014, our certificates of deposit as well as our marketable securities have been recorded at an estimated fair value of $24,757,000 and $23,262,000 in short-term and long-term investments, respectively.
	Investments consisted of the following at December 31, 2014 (in thousands):
			Amortized Cost		Unrealized			Unrealized			Other-		Fair		Cash and Cash Equivalents		Short-term		Long-term
					Gains			Losses			Than-		Value				Investments		Investments
											Temporary
											Impairment
											Losses
	Cash		$	44,785	$	-		$	-		$	-	$	44,785	$	44,785	$	-	$	-
	Money market funds			13,321		-			-			-		13,321		13,321		-		-
	Certificates of deposit			12,657		-			-			-		12,657				3,160		9,497
	Marketable securities:
	Corporate securities			10,837		-			(26	)		-		10,811		-		6,229		4,582
	Federal agency securities			9,512		-			(10	)		-		9,502		-		5,009		4,493
	Municipal securities			15,037		15			(3	)		-		15,049		-		10,359		4,690
	Total marketable securities			35,386		15			(39	)		-		35,362		-		21,597		13,765
			$	106,149	$	15		$	(39	)	$	-	$	106,125	$	58,106	$	24,757	$	23,262
	We did not have certificates of deposit or marketable securities at December 31, 2013.
	The amortized cost and estimated fair value of the marketable securities at December 31, 2014, by maturity, are shown below (in thousands):
			31-Dec-14
			Amoritzed Cost		RFair Value
	Marketable securities:
	Due in one year or less		$	21,597	$	21,597
	Due after one year through 5 years			13,789		13,765
	Due after 5 years through 10 years			-		-
	Due after 10 years			-		-
			$	35,386	$	35,362
	The following table shows the gross unrealized losses and the fair value of our investments, with unrealized losses that are not deemed to be other-than-temporarily impaired aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2014 (in thousands):
			31-Dec-14
			Less Than 12 Months					Greater Than 12 Months
			Fair Value		Unrealized Loss			Fair Value			Unrealized Loss
	Marketable securities:
	Corporate securities		$	9,809	$	(26	)	$	-		$	-
	Federal agency securities			6,490		(10	)		-			-
	Municipal securities			1,832		(3	)		-			-
			$	18,131	$	(39	)	$	-		$	-
	As of December 31, 2014, we have concluded that the unrealized losses on our marketable securities are temporary in nature. Marketable securities are reviewed quarterly for possible other-than-temporary impairment. This review includes an analysis of the facts and circumstances of each individual investment such as the severity of loss, the expectation for that security’s performance and the creditworthiness of the issuer. Additionally, we do not intend to sell, and it is not probable that we will be required to sell, any of the securities before the recovery of their amortized cost basis.

Note_4_Fair_Value_Measurement

Note 4 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4.     Fair Value Measurement
	At December 31, 2014, we held short-term and long-term investments, as described in Note 3, that are required to be measured at fair value on a recurring basis.  All available-for-sale investments held by us at December 31, 2014 have been valued based on Level 2 inputs. Available-for-sale securities classified within Level 2 of the fair value hierarchy are valued utilizing reports from third-party asset managers that hold our investments, showing closing prices on the last business day of the period presented. These asset managers utilize an independent pricing source to obtain quotes for most fixed income securities, and utilize internal procedures to validate the prices obtained. In addition, we use an independent third-party to perform price testing, comparing a sample of quoted prices listed in the asset managers’ reports to quotes listed through a public quotation service.
	Our investments measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820,
	Fair Value Measurements and Disclosures
	, at December 31, 2014 were as follows (in thousands):
		Fair Value Measurement at Reporting Date
		December 31,		Quoted		Significant		Significant Unobservable
		2014		Prices in		Other		Inputs
				active		Observable		(Level 3)
				Markets		Inputs
				(Level 1)		(Level 2)
	Marketable securities:
	Corporate securities	$	10,811	$	-	$	10,811	$	-
	Federal agency securities		9,502		-		9,502		-
	Municipal securities		15,049		-		15,049		-
	Total assets measured at fair value	$	35,362	$	-	$	35,362	$	-
	We did not have any certificates of deposit or marketable securities at December 31, 2013.

Note_5_Inventories

Note 5 - Inventories	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Inventory Disclosure [Text Block]	5.        Inventories
	Inventories are stated at lower of cost or market. Cost, which includes amounts related to materials and costs incurred by our contract manufacturers, is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
	The components of inventories, net of allowances, are as follows (in thousands):
		December 31,			December 31,
		2014			2013
	Finished goods	$	30,998		$	8,084
	Work-in-process		4,316			3,886
	Raw materials and supplies		2,785			2,558
	Total inventories		38,099			14,528
	Less: non-current work-in-process		(3,318	)		-
		$	34,781		$	14,528
	As of December 31, 2014 and 2013, raw materials inventories consisted of raw materials used in the manufacture of our active pharmaceutical ingredient (“API”) in our U.S.-based, state-of-the-art dronabinol manufacturing facility and component parts used in the manufacture of Subsys. Work-in-process consisted of actual production costs, including facility overhead and tolling costs of in-process Dronabinol SG Capsule and Subsys products. Finished goods inventories consisted of finished Dronabinol SG Capsule and Subsys products. Non-current work-in-process represent those inventories pending FDA approval which is not expected before December 31, 2015, and are included in other assets in our consolidated balance sheets.

Note_6_Property_and_Equipment

Note 6 - Property and Equipment	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6.        Property and Equipment
	Property and equipment are comprised of the following (in thousands):
			Estimated
			Useful Life			As of December 31,
			(in years)			2014			2013
	Computer equipment		3	-	5	$	1,530		$	713
	Scientific equipment		5	-	7		5,928			3,379
	Furniture		5	-	7		1,545			487
	Manufacturing equipment		5	-	10		13,101			8,098
	Leasehold improvements			*			16,688			3,869
	Less: accumulated depreciation and amortization						(8,920	)		(6,419	)
	Total fixed assets					$	29,872		$	10,127
	*	The estimated useful life of the leasehold improvements is the lesser of the lease term or the estimated useful life.
	Total depreciation and amortization expense for the years ended December 31, 2014 and 2013 was $2,500,000 and $1,788,000, respectively.

Note_7_Debt

Note 7 - Debt	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Debt Disclosure [Text Block]	7
	.
	Debt
	On September 30, 2014, our $15,000,000 secured revolving credit facility (the “Facility”), which we entered into in October 2013 with JPMorgan Chase Bank, N.A. matured. As of December 31, 2013, no amounts were outstanding under the Facility.
	Upon the May 2013 closing of our IPO, we paid off all indebtedness under our previous line of credit and converted several notes due to a principal stockholder into common stock.

Note_8_Commitments_and_Conting

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8.        Commitments and Contingencies
	Lease Commitments
	We lease facilities under non-cancelable operating lease agreements. Future minimum commitments for these operating leases in place as of December 31, 2014, with a remaining non-cancelable lease term in excess of one year, are as follows (in thousands):
	Years ending December 31,
	2015	$	1,896
	2016		2,062
	2017		1,989
	2018		1,770
	2019		1,795
	Thereafter		5,160
	Total	$	14,672
	The terms of certain lease agreements provide for rental payments on a graduated basis. We recognize rent expense on the straight-line basis over the lease period and have accrued for rent expense incurred but not paid. Rent expense under operating leases for the years ended December 31, 2014 and 2013 was approximately $1,698,000 and $498,000, respectively.
	Defined Contribution Retirement Plans (401(k) Plan)
	We sponsor a 401(k) plan covering all full-time employees. Participants may contribute up to the legal limit. The 401(k) plan provides for employee contributions, and beginning October 2014, our matching contribution is 50 percent of the first 6 percent of earnings contributed by each participant.
	Contractual Commitments
	Manufacture and Supply Agreements
	We maintain certain manufacture and supply agreements with third party vendors for the manufacturing, processing, and packaging of Subsys and Dronabinol SG Capsule which expire in 2016. As of December 31, 2014, our remaining estimated annual contractual obligations under these agreements are not material.
	Contingent Consideration
	In connection with a reverse merger we made in 2010, selling stockholders obtained certain non-transferable contingent payment rights. These rights entitle the selling stockholders to receive cash payments aggregating $20,000,000 (equivalent to $0.70402 per share) if, prior to the five-year anniversary of the acqusition, the FDA approves a New Drug Application for any one or more of the acquired company’s product candidates that were under development at the time of the acqusition. The distribution is payable within nine months of FDA approval. We believe it is not probable that the contingent consideration will be paid.
	Legal Matters
	Other than the matters that we have disclosed below, we from time to time become involved in various ordinary course legal and administrative proceedings, which include intellectual property, commercial, governmental and regulatory investigations, employee related issues and private litigation, which we do not believe are either individually, or in the aggregate, likely to have a material adverse effect on our results of operations and financial condition.
	Notwithstanding that the foregoing legal and governmental proceedings are inherently unpredictable and, in part, beyond our control, and unless otherwise indicated, we cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss, or range of loss, if any, that may result from these proceedings generally described above or specifically described below. An adverse outcome in any of these proceedings could have a material adverse effect on our business, financial condition, results of operations and cash flows, and could cause the market value of our common shares to decline.
	Government Proceedings
	Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. The following is a brief description of pending governmental investigations which we believe are potentially material at this time. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding whether we deem them to be material or not.
	Department of Health and Human Services Investigation.
	We received a subpoena, dated December 9, 2013, from the Office of Inspector General of the Department of Health and Human Services, or HHS, in connection with an investigation of potential violations involving HHS programs. The subpoena was issued in connection with an investigation by the U.S. Attorney’s Office for the Central District of California. The subpoena requests documents regarding our business, including the commercialization of Subsys. We are cooperating with this investigation and have produced documents in response to the subpoena and have provided other requested information.
	Health Insurance Portability and Accountability Act Investigation.
	On September 8, 2014, we received a subpoena issued pursuant to the Health Insurance Portability and Accountability Act of 1996, as amended, from the U.S. Attorney’s Office for the District of Massachusetts. The subpoena requests documents regarding Subsys, including our sales and marketing practices related to this product. We are cooperating with this investigation and have produced documents in response to the subpoena and have provided other requested information.
	We believe that the probability of unfavorable outcome or loss related to these governmental proceedings and an estimate of the amount or range of loss, if any, from an unfavorable outcome are not determinable at this time. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters. However, responding to government investigations, defending any claims raised, and any resulting fines, restitution, damages and penalties, settlement payments or administrative actions, as well as any related actions brought by shareholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our business.
	Federal Securities Litigation
	Between May 15 and May 19, 2014, two complaints (captioned Larson v. Insys Therapeutics, Inc., Case No. 14-cv-01043-GMS) and (Li vs. Insys Therapeutics, Inc., Case No 14-cv-01077-DGC) were filed in the U.S. District Court for the District of Arizona, or Arizona District Court, against us and certain of our current officers. The complaints were brought as purported class actions, on behalf of purchasers of our common stock. In general, the plaintiffs allege that the defendants violated federal securities laws by making intentionally false and misleading statements regarding our business and operations, therefore artificially inflating the price of our common stock. The plaintiffs seek unspecified monetary damages and other relief. On July 14, 2014, several purported shareholders filed motions to consolidate the two cases, appoint a lead plaintiff, and appoint lead counsel. On August 29, 2014, the Arizona District Court issued an order consolidating the action, appointing Hongwei Li as lead plaintiff, and appointing the lead counsel. Lead plaintiffs complaint was filed on October 27, 2014. On December 11, 2014, we moved to dismiss the amended consolidated complaint. The parties have filed a motion to stay the action pending a mediation in connection with a potential resolution of the action.
	General Litigation and Disputes
	Kottayil vs. Insys Pharma, Inc.
	On September 29, 2009, Insys Pharma, Inc., our wholly owned subsidiary, and certain of our officers and the five directors who comprised the Insys Pharma board of directors as of June 2009, as well as their spouses, were named as defendants in a lawsuit in the Superior Court of the State of Arizona, Maricopa County, or the Arizona Superior Court, brought by Santosh Kottayil, Ph.D., certain of his family members and a trust of which Dr. Kottayil is the trustee. Dr. Kottayil formerly served as President, Chief Scientific Officer and a director of Insys Pharma, among other positions. The complaint brought a cause of action for statutory and common law appraisal of Dr. Kottayil’s Insys Pharma common stock. The cause of action for appraisal relates to a reverse stock split that Insys Pharma effected in June 2009, which resulted in Dr. Kottayil’s ownership position becoming a fractional share of Insys Pharma common stock. Following the reverse stock split, Insys Pharma cancelled all resulting fractional shares, including the fractional share held by Dr. Kottayil, and offered a cash payment in lieu of the fractional shares. The complaint also brought causes of action for breach of fiduciary duty, fraud and negligent misrepresentation in the defendants’ dealings with Dr. Kottayil on the subject of his compensation and stock ownership in Insys Pharma. In January 2010, the plaintiffs added claims seeking to rescind Dr. Kottayil’s assignment to Insys Pharma of his interest in all of the fentanyl and dronabinol patent applications previously assigned to Insys Pharma and to recover the benefits of those interests. Dr. Kottayil is seeking, among other relief, the fair value of his Insys Pharma common stock as of June 2, 2009, compensatory and punitive damages, and rescission of all assignments to Insys Pharma of his interest in the patent applications, as well as attorneys’ fees, costs and interest.
	In February 2010, Insys Pharma and the other defendants answered and filed counter-claims to Dr. Kottayil’s amended complaint. The counter-claims include actions for breach of fiduciary duty, fraud and negligent misrepresentations and omissions with respect to the time during which Dr. Kottayil was employed at Insys Pharma. The counter-claims, among other relief, seek compensatory and punitive damages.
	Discovery on all of the foregoing claims was completed and a trial was scheduled to commence on January 27, 2014; however, on January 22, 2014, the court vacated the trial and granted plaintiffs leave to file an amended complaint to add Insys Therapeutics, Inc. as a defendant.
	On January 29, 2014, the plaintiffs filed a second amended complaint in the Arizona Superior Court in which Insys Therapeutics, Inc. was also named as defendant in this lawsuit. This amended complaint filed by plaintiffs re-alleges substantially the same claims set forth in the prior complaint, except that plaintiffs now allege that they are entitled to rescissory damages, plaintiffs have also added our majority stockholder, a private trust, as a defendant to the breach of fiduciary duty claim and plaintiffs have revised their fraud claim against the Insys Pharma director defendants.
	On February 25, 2014, we filed a Motion to Dismiss the Kottayil Plantiffs’ claims for a statutory and common law appraisal. The motion was denied on May 2, 2014.
	The trial commenced on December 1, 2014 with the evidence phase of the trial completing on January 29, 2015.
	Insys Therapeutics, Inc. vs. Mylan Pharmaceuticals
	.
	On or around May 30, 2013, we filed a lawsuit against Mylan Pharmaceuticals, or Mylan, seeking a declaration that the parties’ Supply and Distribution Agreement dated May 20, 2011, or the Distribution Agreement, had been terminated because of Mylan’s material breach of the Distribution Agreement.  Mylan removed the action to the United States District Court for the District of Arizona, or the District Court, as Case No. 2:13-cv-01112-DGC, and moved to compel arbitration and sought a preliminary injunction.  The District Court compelled arbitration and issued a preliminary injunction requiring that the Distribution Agreement continue in full force and effect pending the outcome of arbitration. The District Court then dismissed the lawsuit.
	On May 31, 2013, Mylan filed a demand with the American Arbitration Association, Case No. 55 122 00119 13.  Mylan’s demand alleged that we were in breach of the Distribution Agreement.  On July 10, 2013, we filed a response to Mylan’s demand, denying we were in breach of the Distribution Agreement, and asserting counterclaims based on Mylan’s material breach of the Distribution Agreement and the duty of good faith and fair dealing.
	On January 21, 2014, Mylan filed a second new lawsuit against us with the District Court, as Case No. 2:14-cv-00119-GMS, asserting a claim for declaratory judgment and seeking a temporary restraining order and preliminary injunction relating to our notice of termination of the Distribution Agreement with respect to the parties’ failure to agree on floor pricing.  On January 24, 2014, we responded in opposition to the application for temporary restraining order and preliminary injunction, or Application.  A hearing was initially set for April 3, 2014.  After stipulation of the parties to postpone the hearing, the Court denied all pending motions as moot on April 2, 2014. The Application was dismissed by the Court with prejudice on June 2, 2014. After the Application was dismissed, Mylan filed a Motion to Enforce a draft settlement agreement between the parties. We responded in opposition and the District Court denied Mylan’s motion on September 12, 2014. We have moved for sanctions against Mylan for filing the motion to enforce and we intend to seek damages and attorneys’ fees as part of this arbitration.
	On September 23, 2014, the three member arbitration panel held a preliminary hearing wherein it decided that the arbitration proceeding would be bifurcated. The first phase of the proceeding will determine whether there has been a material breach of the Agreement. If either party is successful in establishing its claims during this first phase then there will be a second phase of the arbitration to determine damages.
	In November 2014, the arbitration panel held Phase I of the arbitration proceeding which we anticipate will resolve (1) whether Mylan materially breached the Agreement by failing to accept the delivery of conforming shipments of product in October 2012, January 2014 and March 2014; (2) whether Mylan has materially breached the parties’ Supply and Distribution Agreement by failing to use commercially reasonable efforts to market and sell the product; and (3) whether we are in breach of the Agreement by delivering non-conforming product. If we are successful in our claims, the Panel will schedule a Phase II of the arbitration to determine the amount, if any, of damages suffered because of the breach of the Supply and Distribution Agreement. The arbitration panel had not yet delivered a Phase I decision as of March 3, 2015.
	We believe that the probability of unfavorable outcome or loss related to all of the above litigation matters and an estimate of the amount or range of loss, if any, from an unfavorable outcome are not determinable at this time. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters but the range possible outcomes on these matters is very broad and we are not able to provide a reasonable estimate of our potential liability, if any, nor are we able to predict the outcome of each litigation matter. For instance, in the Kottayil matter, if the patent assignments are successfully rescinded, we may not have exclusive patent rights covering our fentanyl and dronabinol product candidates, and such patent rights may not be available to us on acceptable terms, if at all, which would have a material adverse effect on our business. Responding to each of these litigation matters, defending any claims raised, and any resulting fines, restitution, damages and penalties, or settlement payments as well as any related actions brought by shareholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our business.

Note_9_Equity

Note 9 - Equity	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9.        Equity
	Preferred Stock
	Prior to our May 2013 IPO, we had outstanding shares of convertible preferred stock that were convertible into common stock on a one-to-0.57377 basis and, until converted, were entitled to the voting and dividend rights of the same number of shares of common stock into which they were convertible. Each share of convertible preferred stock automatically converted into shares of our common stock immediately prior to the closing of our initial public offering of common stock at the conversion ratio.
	In August, 2014, we entered into a Rights Agreement with respect to a newly-designated Series A Participating Preferred Stock. In connection with the Rights Agreement, our Board of Directors declared a dividend distribution of the right to purchase one one-hundredth of one share of our newly designated Series A Junior Participating Preferred Stock, par value $0.001 per share (a “Right”) for each outstanding share of common stock, par value $0.01 per share, held by the stockholders of the Company at the close of business on September 1, 2014 (the “Record Date”).
	Each Right entitles the registered holder to purchase from us one one-hundredth of a share of preferred stock (each, a “Preferred Share” and collectively, the “Preferred Shares”) at a price of $160 per one one-hundredth of a Preferred Share (the “Purchase Price”), subject to adjustment. Each one one-hundredth of a Preferred Share has the designations, powers, privileges, preferences, rights, qualifications, limitations and restrictions that are designed to make it the economic equivalent of one share of common stock.
	The Rights will not become exercisable until the earlier to occur of the close of business on (i) the tenth calendar day following acquisition by any person, entity or group of affiliated or associated persons of beneficial ownership of 15% or more of our outstanding shares of common stock (an “Acquiring Person”) or (ii) the tenth business day (or such later date as may be determined by action of the Board prior to such time as any person or entity becomes an Acquiring Person) following the date of commencement of, or the first announcement of, an intention to commence, a tender offer or exchange offer, the consummation of which would result in any person or entity or group of persons or entities acting in concert becoming an Acquiring Person (the earlier of such dates being called the “Distribution Date”). Until the Distribution Date, the Rights will be transferable with and only with our Common Shares. The Rights will expire ten years after the execution of the Rights Agreement unless the Rights are earlier redeemed or exchanged by us.
	Each Preferred Share is entitled to a minimum preferential quarterly dividend payment equal to the greater of $1.00 per share or 100 times the aggregate per share price of all cash and non-cash dividends declared per share of common stock. In the event of liquidation, the holders of the Preferred Shares would be entitled to a minimum preferential liquidation payment of $100 per share plus an amount equal to accrued and unpaid dividends and distributions thereon, provided that the Preferred Shares would be entitled to receive an aggregate amount per share equal to 100 times the aggregate amount to be distributed per share to holders of common stock. Each Preferred Share has 100 votes, voting together with the common stock.
	Common Stock
	On February 26, 2014, our board of directors approved a three-for-two stock split of our common stock to be effected through a stock dividend. The record date for the stock split was the close of business on March 17, 2014, with share distribution occurring on March 28, 2014. As a result of the dividend, shareholders received one additional share of Insys Therapeutics, Inc. common stock, par value $0.0002145, for each two shares they held as of the record date. All share and per share amounts have been retroactively restated for the effects of this stock split.
	On May 6, 2014, our shareholders approved an amendment to our certificate of incorporation to increase the authorized shares of common stock from 50,000,000 to 100,000,000 and an amendment to increase the par value for our common stock to $0.01 per share. Our consolidated financial statements and notes herein have been retroactively restated to reflect the impact of these amendments.
	Initial Public Offering
	On May 7, 2013, we completed our IPO, pursuant to which we sold 6,900,000 shares of our common stock (4,600,000 on a pre-split basis) at a price of $5.33 per share ($8.00 on a pre-split basis), which included the underwriters’ exercise of their over-allotment option. As a result of the IPO, we raised a total of $32.5 million in net proceeds after deducting underwriting discounts and commissions of $2.6 million and offering expenses of $1.8 million. Costs directly associated with our IPO were capitalized and recorded as deferred IPO costs prior to the completion of the IPO. These costs have been recorded as a reduction of the proceeds received in arriving at the amount recorded in additional paid-in capital. Upon completion of the IPO, all outstanding shares of our preferred stock were converted into 12,793,290 shares of common stock (8,528,860 on a pre-split basis). Also, upon completion of our IPO, the outstanding balance of principal and accrued interest related to several promissory and demand notes in favor of entities controlled by Dr. John Kapoor in the amount of $59,284,000 were converted into 11,115,512 shares of common stock (7,410,341 at a pre-split basis).

Note_10_Stockbased_Compensatio

Note 10 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10.       Stock-based Compensation
	We currently have the following stock-based incentive plans:
	2013 Employee Stock Purchase Plan
	The 2013 Employee Stock Purchase Plan (the “ESPP”) was adopted by our board of directors and approved by our stockholders, and became effective in connection with our initial public offering in May 2013. The ESPP authorizes the issuance of 262,500 shares of common stock (175,000 on a pre-split basis) pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2014 through January 1, 2023, by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 300,000 shares (200,000 on a pre-split basis), or (c) a number determined by our board of directors that is less than (a) and (b). The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the “Code”). As of December 31, 2014, 546,112 shares of common stock have been purchased under the ESPP.
	2013 Equity
	Incentive Plan
	The 2013 Equity Incentive Plan (the “2013 Plan”) is the successor to and continuation of the 2006 Equity Incentive Plan and the Insys Pharma, Inc., Amended and Restated Equity Incentive Plan. The 2013 Plan was adopted by our board of directors and approved by our stockholders, and became effective in connection with our initial public offering in May 2013. The 2013 Plan provides for the grant of stock awards, including stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards, to our employees, directors and consultants. The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2014 through January 1, 2023, by the lesser of (a) 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (b) a number of shares of common stock that may be determined each year by the Registrants board of directors that is less than the preceeding clause (a). As of December 31, 2014, options to purchase 2,808,111 shares of common stock were outstanding and 197,225 shares remained available for future grant.
	2006 Equity Incentive Plan
	The 2006 Equity Incentive Plan (the “2006 Plan”) provided for the grant of stock awards, including stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards, to our employees, directors and consultants. The 2006 Plan was adopted in April 2006. As of December 31, 2014, options to purchase 728,857 shares of common stock were outstanding. There were no unvested options outstanding under the Plan as of December 31, 2014. The Plan has been terminated and we will not grant additional equity awards under the Plan.
	Awards under the 2006 Plan generally consist of stock options that have an exercise price equal to the fair market value of our common stock on the date of grant, a ten-year term, and vest ratably over four years, subject to continuous employment. Stock awards granted to our non-employee directors under the 2006 Plan typically vest one year from the date of grant. Awards under the 2006 Plan vest immediately upon a change in control. Although the 2006 Plan provides for the issuance of performance units and performance shares, we have not made grants of these types of awards.
	Insys Pharma, Inc. Amended and Restated Equity Incentive Plan
	Insys Pharma, Inc.’s Amended and Restated Equity Incentive Plan (the “Plan”) provided for the grant of stock options to employees, directors and consultants to acquire Insys Pharma’s voting and non-voting common stock. The Plan was originally adopted by Insys Pharma in December 2002 and was amended and restated in June 2006. In connection with our reverse acquisition of Insys Pharma in November 2010, all of the outstanding options granted under the Plan were assumed by us and were converted into options to purchase shares of our common stock at the exchange ratio set forth in the merger agreement. As of December 31, 2014, options to purchase an aggregate of 316,613 shares of our common stock under the Plan were outstanding. There were no unvested options outstanding under the Plan as of December 31, 2014. The Plan has been terminated and we will not grant additional equity awards under the Plan.
	Option awards under the Plan were generally granted with an exercise price equal to the fair market value of Insys Pharma’s common stock on the date of grant. Option awards under the Plan typically have a ten-year life and vest within the first two years of the grant, subject to continuous employment. Option awards granted to Insys Pharma’s non-employee consultants under the Plan typically vest within two years from the date of grant. These options are marked to market at each reporting period. The expense associated with these adjustments has historically been immaterial.
	Amounts recognized in the consolidated statements of comprehensive income with respect to our stock-based compensation plans were as follows (in thousands):
		Years Ended December 31,
		2014			2013
	Research and development	$	5,498		$	915
	General and administrative		9,791			5,424
	Total cost of stock-based compensation	$	15,289		$	6,339
	Included in stock-based compensation for the year ended December 31, 2014 was approximately $4,016,000 of expense associated with the accelerated vesting of option awards related to two terminated employees.
	The following table summarizes stock option activity during the years ended December 31, 2014 and 2013:
		Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual		(in millions)
							Term (in years)
	Outstanding as of December 31, 2012		3,258,860		$	2.12
	Granted		2,230,050		$	9.71
	Cancelled		(87,444	)	$	5.71
	Exercised		(903,977	)	$	2.31
	Outstanding as of December 31, 2013		4,497,489		$	5.79
	Granted		1,698,599		$	29.13
	Cancelled		(534,112	)	$	15.42
	Exercised		(1,808,395	)	$	4.95
	Outstanding as of December 31, 2014		3,853,581		$	15.14		8.3	$	104.1
	Vested and exercisable as of December 31, 2013		1,810,653		$	2.8		7.05	$	41.7
	Vested and exercisable as of December 31, 2014		1,330,360		$	7.9		7.2	$	45.6
	The aggregate intrinsic value for stock options outstanding and exercisable is defined as the positive difference between the fair market value of our common stock and the exercise price of the stock options. As of December 31, 2014, we expect to recognize $34,118,000 of stock-based compensation for our outstanding options over a weighted-average period of 3.0 years.
	Cash received from option exercises under all share-based payment arrangements for the years ended December 31, 2014 and 2013, was $8,956,000 and $2,102,000. For the years ended December 31, 2014 and 2013, we recorded net reductions of $22,003,000 and $2,745,000, respectively, of our federal and state income tax liability, with an offsetting credit to additional paid-in capital resulting from the excess tax benefits related to exercised stock options.
	Stock Option Valuation Information
	The weighted-average assumptions used to estimate the fair value of employee stock options granted during the periods presented are as follows:
		2014			2013
	Expected volatility		69.30%			73.54%
	Risk-free interest rate		1.72%			2.04%
	Expected term (in years)		6			7
	Expected dividend yield		0.00%			0.00%
	For the years ended December 31, 2014 and 2013, the weighted-average estimated fair value per option granted was $21.05 and $10.07, respectively.

Note_11_Income_Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11.     Income Taxes
	Income tax (benefit) expense consists of the following (in thousands):
		Years Ended December 31,
		2014			2013
	Current income taxes:
	Federal	$	22,500		$	2,281
	State and local		3,874			957
	Total current income tax		26,374			3,238
	Deferred income taxes:
	Federal		867			(9,123	)
	State and local		(1,042	)		(2,915	)
	Total deferred income tax		(175	)		(12,038	)
	Provision (benefit) for income taxes	$	26,199		$	(8,800	)
	As of December 31, 2014, we had approximately $1.6 million of federal net operating loss carryforwards (“NOLs”) all of which are subject to a significant Section 382 limitation. Under Section 382 of the Code, substantial changes in our ownership may limit the amount of NOLs that can be utilized annually in the future to offset taxable income, if any. Specifically, this limitation may arise in the event of a cumulative change in ownership of our company of more than 50% within a three-year period as determined under the Code, which we refer to as an ownership change. Any such annual limitation may significantly reduce the utilization of these NOLs before they expire. Our ability to utilize federal NOLs created prior to the NeoPharm merger is significantly limited. For federal tax purposes, the Section 382 NOL carryforward is limited on an annual basis and begins expiring in 2018.
	For state tax purposes, we had approximately $272.0 million of state NOLs at December 31, 2014, including the excess tax deductions from the exercise of stock options. Approximately $269.5 million of these NOLs relate only to Illinois. Based on projections, we estimate that approximately $263.2 million of these Illinois NOLs will not be utilized. For this reason, we recorded a valuation allowance for the estimated tax benefit relating to this amount, or $20.4 million. Generally, the state NOL carryforwards begin expiring in 2016 if not utilized. The Illinois NOLs begin expiring in 2015 if not utilized.
	At December 31, 2012, a full valuation allowance was placed on our net deferred tax assets because we determined that it was more likely than not that we would not benefit from these tax attributes in the future. During the fourth quarter of 2013, we determined it was more likely than not that we would be able to utilize nearly all types of our deferred tax assets, including all federal net operating loss carryforwards. This determination was made based on our profitability in 2013 and our expectations of future profitability. Accordingly, we reversed the deferred tax asset valuation allowance associated with the majority of our deferred tax assets.
	Deferred Income Taxes
	The tax effects of temporary differences and carry forwards that give rise to the deferred tax assets and liabilities are comprised of the following as of December 31 (in thousands):
	Deferred tax assets:	2014			2013
	NOLs and credits	$	24,683		$	23,429
	Start-up expenditures		3,349			3,613
	Stock-based compensation		4,351			2,411
	Deferred revenue and allowances		2,516			2,310
	Expenses currently not deductible for tax purposes		3,884			2,116
	Other		149			-
	Gross deferred tax assets		38,932			33,879
	Deferred tax asset valuation allowance		(20,402	)		(20,684	)
	Deferred tax assets		18,530			13,195
	Deferred tax liabilities:
	Federal impact of state taxes		(1,384	)		(1,021	)
	Property and equipment		(4,354	)		(136	)
	Prepaid expenses		(579	)		-
	Net deferred tax assets	$	12,213		$	12,038
	In assessing the realization of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We also consider the scheduled reversal of deferred tax liabilities, projected future taxable income or losses, and tax planning strategies in making this assessment. Based upon our current net income and projections for future taxable income over the periods in which the deferred tax assets are deductible, we believe that, with the exception of the Illinois NOL discussed above, the realization of these tax assets is more likely than not. As such, with the exception of the valuation allowance that has been placed on the future tax benefit relating to our Illinois NOLs, no other valuation allowance exists on our deferred tax assets at December 31, 2014.
	Effective Tax Rate Reconciliation:
	Our federal statutory tax rate is 35%, while our effective tax rate was 40.8% for the year ended December 31, 2014 as set forth below:
		2014			2013
	U.S. statutory tax rate		35	%		35	%
	Increase (reduction) of income taxes resulting from:
	State income taxes, net of federal benefit		2.9	%		11.8	%
	Non-deductible litigation expense		3	%		-
	Other non-deductible and includible items and credits		0.6	%		2.3	%
	Research and other credits		(2.2	)%		(1.8	)%
	Uncertain tax positions		1.8	%		-
	Other		(0.3	)%		(0.6	)%
	Change in valuation allowance		0	%		(74.6	)%
	Total (benefit) provision for income taxes		40.8	%		(27.9	)%
	The following is a reconciliation of the beginning and ending amounts of unrecognized tax benefits (in thousands):
		Years Ended December 31,
		2014			2013
	Beginning balance	$	325		$	-
	Additions based on current year tax positions		450			270
	Additions based on prior year tax positions		4,591			55
	Ending balance	$	5,366		$	325
	The Company establishes reserves when it is more likely than not that the Company will not realize the full tax benefit of a position. The Company had a reserve of $5,366,000 as of December 31, 2014, mostly related to tax credits of $1,606,000, state and local income tax filing positions of $2,503,000, and $1,257,000 of other permanent differences.
	No significant penalties or interest are included in income taxes or accounted for on the balance sheet related to unrecognized tax positions as of December 31, 2014.
	Tax years subsequent to 2010 remain open to examination by federal and state taxing authorities. In addition, our reverse acquisition NOLs remain open to examination.

Note_12_Net_Income_Per_Share

Note 12 - Net Income Per Share	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Earnings Per Share [Text Block]	12.     Net Income per Share
	Basic net income per common share is computed by dividing the net income by the weighted average number of common shares outstanding during the period. The diluted income per share further includes any common shares available to be issued upon exercise of outstanding stock options if such inclusion would be dilutive.
	The following table sets forth the computation of basic and diluted net income per common share (in thousands, except per share amounts):
		Years Ended
		December 31,
		2014		2013
	Historical net income per share - Basic
	Numerator:
	Net income	$	37,977	$	40,377
	Denominator:
	Weighted average number of common shares outstanding		34,379,535		25,919,768
	Basic net income per common share	$	1.1	$	1.56
	Historical net income per share - Diluted
	Numerator:
	Net income	$	37,977	$	40,377
	Denominator:
	Weighted average number of common shares outstanding		34,379,535		25,919,768
	Effect of dilutive stock options		2,288,031		2,814,849
	Weighted average number of common shares outstanding		36,667,566		28,734,617
	Diluted net income per common share	$	1.04	$	1.41
	The calculation of diluted net income per common share excludes the effects of 890,186 outstanding stock options for the year ended December 31, 2014 as the impact of these options was anti-dilutive. There were no anti-dilutive share equivalents for the year ended December 31, 2013.

Note_13_Product_Lines_Concentr

Note 13 - Product Lines, Concentration of Credit Risk and Significant Customers	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	13.      Product Lines, Concentration of Credit Risk and Significant Customers
	We are engaged in the business of developing and selling pharmaceutical products. We have two product lines, consisting of Subsys and Dronabinol SG Capsule. Our chief operating decision-maker evaluates revenues based on product lines.
	The following tables summarize our net revenue by product line, as well as the percentages of revenue by route to market (in thousands):
		Net Revenue by Product Line
		Years Ended December 31,
		2014			2013
	Subsys	$	219,530		$	95,740
	Dronabinol SG Capsule		2,595			3,549
	Total net revenue	$	222,125		$	99,289
		Percent of Revenue by Route to Market
		Years Ended December 31,
		2014			2013
	Pharmaceutical wholesalers		99	%		96	%
	Generic pharmaceutical distributors		1	%		4	%
			100	%		100	%
	All our products are sold in the United States of America.
	Product shipments to four pharmaceutical wholesalers accounted for 38%, 22%, 14% and 14% of shipments of Subsys for the year ended December 31, 2014. Product shipments to four pharmaceutical wholesalers accounted for 30%, 21%, 20% and 19% of shipments of Subsys for the year ended December 31, 2013. Four pharmaceutical wholesalers’ accounts receivable balances accounted for 26%, 24%, 23% and 14% of gross accounts receivable as of December 31, 2014. Four pharmaceutical wholesalers’ accounts receivable balances accounted for 40%, 21%, 17% and 14% of accounts receivable as of December 31, 2013.
	Currently, for Subsys, we use one vendor as our sole supplier of the active pharmaceutical ingredient in this product.
	Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions and generally limit the amount of credit exposure to the amount of FDIC coverage. However, periodically during the year, we maintain cash in financial institutions in excess of the current FDIC insurance coverage limit of $250,000. We perform ongoing credit evaluations of our customers’ financial condition but do not typically require collateral to support customer receivables. We established an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

Note_14_Supplemental_Financial

Note 14 - Supplemental Financial Information	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	14.      Supplemental Financial Information
	A summary of additions and deductions related to the allowances for accounts receivable for the years ended December 31, 2014 and 2013 are as follows (in thousands):
		Balance		Charged to			Utilization		Balance at
		at Beginning of		Costs and					End of
		Year		Expenses					Year
	Allowance for doubtful accounts:
	Year ended December 31, 2014	$	-	$	398	$	-		$	398
	Year ended December 31, 2013	$	-	$	-	$	-		$	-
	Allowance for sales wholesaler discounts, prompt pay discounts, stocking allowances, and chargebacks:
	Year ended December 31, 2014	$	2,748	$	22,395	$	(19,725	)	$	5,418
	Year ended December 31, 2013	$	834	$	8,512	$	(6,598	)	$	2,748

Significant_Accounting_Policie

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The consolidated financial statements include the accounts of Insys Therapeutics, Inc. and its wholly-owned subsidiary, Insys Pharma, Inc. (“Insys Pharma”). All significant intercompany balances and transactions have been eliminated in the accompanying consolidated financial statements.
Reclassification, Policy [Policy Text Block]
	Reclassification
	Certain amounts in the 2013 consolidated financial statements have been reclassified to conform to the 2014 presentation.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The carrying values of our financial instruments, including cash, accounts receivable and accounts payable approximate their fair value due to the short term nature of these financial instruments.
	Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 820, “Fair Value Measurement” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	We recognize revenue from the sale of Subsys and Dronabinol SG Capsule. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.
	Subsys
	Subsys was commercially launched in March 2012, and is available through a U.S. Food and Drug Administration (“FDA”) mandated Risk Evaluation and Mitigation program known as the Transmucosal Immediate Release Fentanyl program (“TIRF REMS”). We sell Subsys in the United States to wholesale pharmaceutical distributors, and on a very limited basis directly to retail pharmacies, or collectively our customers, on a wholesale basis, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. Subsys currently has a shelf life of 36 months from the date of manufacture. Given the limited sales history of prescriptions of Subsys prior to the fourth quarter of 2013, we were not able to reliably estimate expected returns of the product at the time of shipment prior to the fourth quarter of 2013. Accordingly, we initially deferred the recognition of revenue and related product costs of Subsys product shipments until the product was dispensed through patient prescriptions. The quantity of prescription units dispensed was estimated using an analysis of third-party information, including TIRF REMS mandated data and third-party market research data. Beginning in the fourth quarter of 2013, we were able to reasonably estimate product returns of Subsys. Therefore, we began recognizing revenue for Subsys sales at the time of shipment. Accordingly, in the fourth quarter of 2013, we recognized a one-time increase of $1.5 million in net product sales of Subsys, representing product sales previously deferred, net of estimated product returns, wholesaler discounts, prompt pay discounts, stocking allowances, patient discount programs, rebates, and chargebacks. Including deferred cost of sales, this change resulted in a one-time $0.9 million increase to operating income for the year ended December 31, 2013.
	We recognize estimated product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future discounts taken. In certain cases, such as patient assistance programs, we recognize the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, we may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Our product sales allowances include:
	Product Returns.
	We allow customers to return product for credit within six months before and up to 12 months following its product expiration date. The shelf life of Subsys is currently 36 months from the date of manufacture. We have monitored actual return history since product launch, which provides us with a basis to reasonably estimate future product returns, taking into consideration the shelf life of product at the time of shipment, shipment and prescription trends, estimated distribution channel inventory levels, and consideration of the introduction of competitive products.
	Because of the shelf life of our products and our return policy of issuing credits on returned product that is within six months before and up to 12 months after its product expiration date, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. Accordingly, we may have to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustments. The allowance for product returns is included in sales allowances.
	Wholesaler Discounts
	.    We offer discounts to certain wholesale distributors based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognize the discount as a reduction of revenue in the same period the related revenue is recognized.
	Prompt Pay Discounts
	.    We offer cash discounts to our customers, generally 2.0% of the sales price, as an incentive for prompt payment. We account for cash discounts by reducing accounts receivable by the full amount and recognize the discount as a reduction of revenue in the same period the related revenue is recognized.
	Stocking Allowances
	.    We may offer discounts and extended payment terms, generally in the month of the initial commercial launch of a new product and on the first order made by certain wholesale distributors and retail pharmacies based on contractually determined rates. We accrue the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognize the discount as a reduction of revenue in the same period the related revenue is recognized.
	Patient Discount Programs
	.    We offer discount card programs to patients for Subsys in which patients receive discounts on their prescriptions that are reimbursed by us to the retailer. We estimate the total amount that will be redeemed based on a percentage of actual redemption applied to inventory in the distribution and retail channel and recognize the discount as a reduction of revenue in the same period the related revenue is recognized. The allowance for patient discount programs is included in accrued sales allowances.
	Rebates
	.    We participate in certain rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, we pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. We estimate and accrue these rebates based on current contract prices, historical and estimated future percentages of products sold to qualified patients and estimated levels of inventory in the distribution channel. Rebates are recognized as a reduction of revenue in the period the related revenue is recognized. The allowance for rebates is included in accrued sales allowances.
	Chargebacks.
	We provide discounts primarily to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the entity paid for the product. We estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. The allowance for chargebacks is included as a reduction to accounts receivable.
	Dronabinol SG Capsule
	Dronabinol SG Capsule was commercially launched in December 2011, and we sell Dronabinol SG Capsule exclusively to Mylan Pharmaceuticals, Inc. (“Mylan”) in the United States under a supply and distribution agreement. Pursuant to the terms of the Mylan agreement, we manufacture Dronabinol SG Capsule under the Mylan label. Mylan distributes Dronabinol SG Capsule and on a monthly basis pays us an amount equal to the value of Dronabinol SG Capsule it sold to wholesale pharmaceutical distributors, less contractually defined deductions for chargebacks, rebates, sales discounts, distribution and storage fees, and royalties. Under the terms of the supply and distribution agreement with Mylan, we are obligated to pay Mylan a royalty of between 10% and 20% on Mylan’s net product sales, and a single digit percentage fee on such sales for distribution and storage services. We bear no risk of product return upon acceptance by Mylan. As Mylan has control over the amount it charges to wholesale pharmaceutical distributors for Dronabinol SG Capsule and the discounts offered to the distributors, the sales price is not fixed and determinable at the date we ship such products to Mylan. Accordingly, we recognize revenue upon Mylan’s sale of products to wholesale distributors, which is the point at which the sales price is fixed and determinable. See Note 8 under the heading “-Legal Matters” of these Notes for a discussion on our ongoing dispute with Mylan.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which at times may exceed FDIC limits.
Receivables, Policy [Policy Text Block]	Accounts Receivable, Net
	Trade accounts receivable are recorded at the invoice amount net of allowances for wholesaler discounts, prompt pay discounts, stocking allowances, and doubtful accounts. See Note 2 – “Revenue Recognition” above for a description of our wholesaler discounts, prompt pay discounts, stocking allowances and chargebacks. We evaluate the collectability of our accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience.
Inventory, Policy [Policy Text Block]	Inventories
	Inventories consist of raw materials, work-in-process and finished product and are valued at the lower of cost (first-in, first-out cost method) or market. Inventory costs are capitalized prior to regulatory approval and product launch based on management’s judgment of probable future commercial use and net realizable value of the inventory. Such judgment incorporates our knowledge and best estimate of where the relevant product is in the regulatory process, our required investment in the product, market conditions, competing products and our economic expectations for the product post-approval relative to the risk of manufacturing the product prior to approval. In evaluating the recoverability of inventories produced in preparation for product launches, we consider the probability that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process, as well as the market for the product in its current state. We could be required to permanently write down previously capitalized costs related to pre-approval or pre-launch inventory upon a change in such judgment, due to a denial or delay of approval by regulatory bodies, a delay in commercialization, or other potential factors including product expiration.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.
Income Tax, Policy [Policy Text Block]	Income Taxes
	We account for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the “NOLs”) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date.
	We record a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations.
	We recognize a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.
	Our policy is to classify interest and penalties associated with income tax liabilities as income tax expense in the statement of operations.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses
	Research and development (“R&D”) costs are expensed when incurred. These costs consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.
Advertising Costs, Policy [Policy Text Block]	Advertising and Marketing
	Advertising and marketing costs are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Expenses
	Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options using the following assumptions:
		?	Exercise price - Prior to May 7, 2013, we determined the exercise price based on valuations using the best information available to management at the time of the valuations. Subsequent to our initial public offering of common stock (“IPO”) on May 7, 2013, the exercise price is equal to the fair market value of the stock on the grant date which is determined based on quoted market prices.
		?	Volatility - Prior to our IPO, we did not have a reliable history of market prices for our common stock. Following our IPO, while we have an active trading market, we do not have sufficient historical data to accurately determine volatility for the period equivalent to the expected term of the stock option grants. Accordingly, we estimate the expected stock price volatility for our common stock by taking the median historical stock price volatility for industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants.
		?	Expected term - The expected term is based on a simplified method which defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards.
		?	Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted.
		?	Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.
		?	Forfeitures - Forfeitures have historically been insignificant.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could materially differ from those estimates.
Segment Reporting, Policy [Policy Text Block]	Segment Information
	FASB ASC No. 280, “Segment Reporting” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (“CODM”), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on our integration and management strategies, we operate in a single reportable segment.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09,
	Revenue from Contracts with Customers
	(ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017.

Note_3_Shortterm_and_Longterm_1

Note 3 - Short-term and Long-term Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Available-for-sale Securities [Table Text Block]		Amortized Cost		Unrealized			Unrealized			Other-		Fair		Cash and Cash Equivalents		Short-term		Long-term
				Gains			Losses			Than-		Value				Investments		Investments
										Temporary
										Impairment
										Losses
	Cash	$	44,785	$	-		$	-		$	-	$	44,785	$	44,785	$	-	$	-
	Money market funds		13,321		-			-			-		13,321		13,321		-		-
	Certificates of deposit		12,657		-			-			-		12,657				3,160		9,497
	Marketable securities:
	Corporate securities		10,837		-			(26	)		-		10,811		-		6,229		4,582
	Federal agency securities		9,512		-			(10	)		-		9,502		-		5,009		4,493
	Municipal securities		15,037		15			(3	)		-		15,049		-		10,359		4,690
	Total marketable securities		35,386		15			(39	)		-		35,362		-		21,597		13,765
		$	106,149	$	15		$	(39	)	$	-	$	106,125	$	58,106	$	24,757	$	23,262
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]		31-Dec-14
		Amoritzed Cost		RFair Value
	Marketable securities:
	Due in one year or less	$	21,597	$	21,597
	Due after one year through 5 years		13,789		13,765
	Due after 5 years through 10 years		-		-
	Due after 10 years		-		-
		$	35,386	$	35,362
Schedule of Unrealized Loss on Investments [Table Text Block]		31-Dec-14
		Less Than 12 Months					Greater Than 12 Months
		Fair Value		Unrealized Loss			Fair Value			Unrealized Loss
	Marketable securities:
	Corporate securities	$	9,809	$	(26	)	$	-		$	-
	Federal agency securities		6,490		(10	)		-			-
	Municipal securities		1,832		(3	)		-			-
		$	18,131	$	(39	)	$	-		$	-

Note_4_Fair_Value_Measurement_

Note 4 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]		Fair Value Measurement at Reporting Date
		December 31,		Quoted		Significant		Significant Unobservable
		2014		Prices in		Other		Inputs
				active		Observable		(Level 3)
				Markets		Inputs
				(Level 1)		(Level 2)
	Marketable securities:
	Corporate securities	$	10,811	$	-	$	10,811	$	-
	Federal agency securities		9,502		-		9,502		-
	Municipal securities		15,049		-		15,049		-
	Total assets measured at fair value	$	35,362	$	-	$	35,362	$	-

Note_5_Inventories_Tables

Note 5 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Inventory, Current [Table Text Block]		December 31,			December 31,
		2014			2013
	Finished goods	$	30,998		$	8,084
	Work-in-process		4,316			3,886
	Raw materials and supplies		2,785			2,558
	Total inventories		38,099			14,528
	Less: non-current work-in-process		(3,318	)		-
		$	34,781		$	14,528

Note_6_Property_and_Equipment_

Note 6 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Property, Plant and Equipment [Table Text Block]		Estimated
		Useful Life			As of December 31,
		(in years)			2014			2013
	Computer equipment	3	-	5	$	1,530		$	713
	Scientific equipment	5	-	7		5,928			3,379
	Furniture	5	-	7		1,545			487
	Manufacturing equipment	5	-	10		13,101			8,098
	Leasehold improvements		*			16,688			3,869
	Less: accumulated depreciation and amortization					(8,920	)		(6,419	)
	Total fixed assets				$	29,872		$	10,127

Note_8_Commitments_and_Conting1

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Years ending December 31,
	2015	$	1,896
	2016		2,062
	2017		1,989
	2018		1,770
	2019		1,795
	Thereafter		5,160
	Total	$	14,672

Note_10_Stockbased_Compensatio1

Note 10 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]		Years Ended December 31,
		2014			2013
	Research and development	$	5,498		$	915
	General and administrative		9,791			5,424
	Total cost of stock-based compensation	$	15,289		$	6,339
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual		(in millions)
							Term (in years)
	Outstanding as of December 31, 2012		3,258,860		$	2.12
	Granted		2,230,050		$	9.71
	Cancelled		(87,444	)	$	5.71
	Exercised		(903,977	)	$	2.31
	Outstanding as of December 31, 2013		4,497,489		$	5.79
	Granted		1,698,599		$	29.13
	Cancelled		(534,112	)	$	15.42
	Exercised		(1,808,395	)	$	4.95
	Outstanding as of December 31, 2014		3,853,581		$	15.14		8.3	$	104.1
	Vested and exercisable as of December 31, 2013		1,810,653		$	2.8		7.05	$	41.7
	Vested and exercisable as of December 31, 2014		1,330,360		$	7.9		7.2	$	45.6
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		2014			2013
	Expected volatility		69.30%			73.54%
	Risk-free interest rate		1.72%			2.04%
	Expected term (in years)		6			7
	Expected dividend yield		0.00%			0.00%

Note_11_Income_Taxes_Tables

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		Years Ended December 31,
		2014			2013
	Current income taxes:
	Federal	$	22,500		$	2,281
	State and local		3,874			957
	Total current income tax		26,374			3,238
	Deferred income taxes:
	Federal		867			(9,123	)
	State and local		(1,042	)		(2,915	)
	Total deferred income tax		(175	)		(12,038	)
	Provision (benefit) for income taxes	$	26,199		$	(8,800	)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred tax assets:	2014			2013
	NOLs and credits	$	24,683		$	23,429
	Start-up expenditures		3,349			3,613
	Stock-based compensation		4,351			2,411
	Deferred revenue and allowances		2,516			2,310
	Expenses currently not deductible for tax purposes		3,884			2,116
	Other		149			-
	Gross deferred tax assets		38,932			33,879
	Deferred tax asset valuation allowance		(20,402	)		(20,684	)
	Deferred tax assets		18,530			13,195
	Deferred tax liabilities:
	Federal impact of state taxes		(1,384	)		(1,021	)
	Property and equipment		(4,354	)		(136	)
	Prepaid expenses		(579	)		-
	Net deferred tax assets	$	12,213		$	12,038
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2014			2013
	U.S. statutory tax rate		35	%		35	%
	Increase (reduction) of income taxes resulting from:
	State income taxes, net of federal benefit		2.9	%		11.8	%
	Non-deductible litigation expense		3	%		-
	Other non-deductible and includible items and credits		0.6	%		2.3	%
	Research and other credits		(2.2	)%		(1.8	)%
	Uncertain tax positions		1.8	%		-
	Other		(0.3	)%		(0.6	)%
	Change in valuation allowance		0	%		(74.6	)%
	Total (benefit) provision for income taxes		40.8	%		(27.9	)%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]		Years Ended December 31,
		2014			2013
	Beginning balance	$	325		$	-
	Additions based on current year tax positions		450			270
	Additions based on prior year tax positions		4,591			55
	Ending balance	$	5,366		$	325

Note_12_Net_Income_Per_Share_T

Note 12 - Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Years Ended
		December 31,
		2014		2013
	Historical net income per share - Basic
	Numerator:
	Net income	$	37,977	$	40,377
	Denominator:
	Weighted average number of common shares outstanding		34,379,535		25,919,768
	Basic net income per common share	$	1.1	$	1.56
	Historical net income per share - Diluted
	Numerator:
	Net income	$	37,977	$	40,377
	Denominator:
	Weighted average number of common shares outstanding		34,379,535		25,919,768
	Effect of dilutive stock options		2,288,031		2,814,849
	Weighted average number of common shares outstanding		36,667,566		28,734,617
	Diluted net income per common share	$	1.04	$	1.41

Note_13_Product_Lines_Concentr1

Note 13 - Product Lines, Concentration of Credit Risk and Significant Customers (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]		Net Revenue by Product Line
		Years Ended December 31,
		2014			2013
	Subsys	$	219,530		$	95,740
	Dronabinol SG Capsule		2,595			3,549
	Total net revenue	$	222,125		$	99,289
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]		Percent of Revenue by Route to Market
		Years Ended December 31,
		2014			2013
	Pharmaceutical wholesalers		99	%		96	%
	Generic pharmaceutical distributors		1	%		4	%
			100	%		100	%

Note_14_Supplemental_Financial1

Note 14 - Supplemental Financial Information (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Allowance for Credit Losses on Financing Receivables [Table Text Block]		Balance		Charged to			Utilization		Balance at
		at Beginning of		Costs and					End of
		Year		Expenses					Year
	Allowance for doubtful accounts:
	Year ended December 31, 2014	$	-	$	398	$	-		$	398
	Year ended December 31, 2013	$	-	$	-	$	-		$	-
	Allowance for sales wholesaler discounts, prompt pay discounts, stocking allowances, and chargebacks:
	Year ended December 31, 2014	$	2,748	$	22,395	$	(19,725	)	$	5,418
	Year ended December 31, 2013	$	834	$	8,512	$	(6,598	)	$	2,748

Note_2_Significant_Accounting_1

Note 2 - Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended		3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
Accounting Policies [Abstract]
Number of Reportable Segments	1
Revenues	$222,125	$99,289
Net Income (Loss) Attributable to Parent	37,977	40,377
Cash Discount, Percent	2.00%
Subsys [Member]
Accounting Policies [Abstract]
Revenues			1,500
Net Income (Loss) Attributable to Parent		$900
Mylan Pharmaceuticals, Inc [Member] | Maximum [Member]
Accounting Policies [Abstract]
Royalty Obligation as Percentage of Net Sales	20.00%
Mylan Pharmaceuticals, Inc [Member] | Minimum [Member]
Accounting Policies [Abstract]
Royalty Obligation as Percentage of Net Sales	10.00%

Note_3_Shortterm_and_Longterm_2

Note 3 - Short-term and Long-term Investments (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]
Certificates of Deposit, at Carrying Value		$0
Marketable Securities		0
Short-term Investments	24,757,000
Long-term Investments	23,262,000
Available-for-sale Securities [Member]
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	24,757,000
Long-term Investments	$23,262,000

Note_3_Shortterm_and_Longterm_3

Note 3 - Short-term and Long-term Investments - Summary of Investments (Details) (USD $)	Dec. 31, 2014
Amortized Cost	$106,149,000
Fair Value	106,125,000
Cash and Cash Equivalents	58,106,000
Short-term Investments	24,757,000
Long-term Investments	23,262,000
Unrealized Losses	-39,000
Unrealized Gains	15,000
Corporate Debt Securities [Member]
Amortized Cost	10,837,000
Fair Value	10,811,000
Short-term Investments	6,229,000
Long-term Investments	4,582,000
Unrealized Losses	-26,000
Municipal Bonds [Member]
Amortized Cost	15,037,000
Fair Value	15,049,000
Short-term Investments	10,359,000
Long-term Investments	4,690,000
Unrealized Losses	-3,000
Unrealized Gains	15,000
US Government Agencies Debt Securities [Member]
Amortized Cost	9,512,000
Fair Value	9,502,000
Short-term Investments	5,009,000
Long-term Investments	4,493,000
Unrealized Losses	-10,000
Marketable Securities [Member]
Amortized Cost	35,386,000
Fair Value	35,362,000
Short-term Investments	21,597,000
Long-term Investments	13,765,000
Unrealized Losses	-39,000
Unrealized Gains	15,000
Cash [Member]
Amortized Cost	44,785,000
Fair Value	44,785,000
Cash and Cash Equivalents	44,785,000
Certificates of Deposit [Member]
Amortized Cost	12,657,000
Fair Value	12,657,000
Short-term Investments	3,160,000
Long-term Investments	9,497,000
Money Market Funds [Member]
Amortized Cost	13,321,000
Fair Value	13,321,000
Cash and Cash Equivalents	$13,321,000

Note_3_Shortterm_and_Longterm_4

Note 3 - Short-term and Long-term Investments - Amortized Cost and Estimated Fair Value of Securities (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Marketable securities:
Due in one year or less	$21,597
Due in one year or less	21,597
Due after one year through 5 years	13,789
Due after one year through 5 years	13,765
	35,386
	$35,362

Note_3_Shortterm_and_Longterm_5

Note 3 - Short-term and Long-term Investments - Gross Unrealized Losses (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Less Than 12 Months Fair Value	$18,131
Less Than 12 Months Unrealized Loss	-39
Corporate Debt Securities [Member]
Less Than 12 Months Fair Value	9,809
Less Than 12 Months Unrealized Loss	-26
Municipal Bonds [Member]
Less Than 12 Months Fair Value	1,832
Less Than 12 Months Unrealized Loss	-3
US Government Agencies Debt Securities [Member]
Less Than 12 Months Fair Value	6,490
Less Than 12 Months Unrealized Loss	($10)

Note_4_Fair_Value_Measurement_1

Note 4 - Fair Value Measurement (Details Textual) (USD $)	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Certificates of Deposit, at Carrying Value	$0
Marketable Securities	$0

Note_4_Fair_Value_Measurement_2

Note 4 - Fair Value Measurement - Investments Measured at Fair Value on a Recurring Basis (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Marketable securities:
Available-for-sale securities	$35,362
Corporate Debt Securities [Member]
Marketable securities:
Available-for-sale securities	10,811
Municipal Bonds [Member]
Marketable securities:
Available-for-sale securities	15,049
US Government Agencies Debt Securities [Member]
Marketable securities:
Available-for-sale securities	9,502
Fair Value, Inputs, Level 2 [Member]
Marketable securities:
Available-for-sale securities	35,362
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Marketable securities:
Available-for-sale securities	10,811
Fair Value, Inputs, Level 2 [Member] | Municipal Bonds [Member]
Marketable securities:
Available-for-sale securities	15,049
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Marketable securities:
Available-for-sale securities	$9,502

Note_5_Inventories_Components_

Note 5 - Inventories - Components of Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finished goods	$30,998	$8,084
Work-in-process	4,316	3,886
Raw materials and supplies	2,785	2,558
Total inventories	38,099	14,528
Less: non-current work-in-process	-3,318
	$34,781	$14,528

Note_6_Property_and_Equipment_1

Note 6 - Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation, Depletion and Amortization	$2,500,000	$1,788,000

Note_6_Property_and_Equipment_2

Note 6 - Property and Equipment - Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Property, Plant and Equipment, gross	16,688	[1]	$3,869	[1]
Less: accumulated depreciation and amortization	-8,920		-6,419
Total fixed assets	29,872		10,127
Computer Equipment [Member]
Property, Plant and Equipment, gross	1,530		713
Computer Equipment [Member] | Maximum [Member]
Estimated Useful Life	5 years
Computer Equipment [Member] | Minimum [Member]
Estimated Useful Life	3 years
Equipment [Member]
Property, Plant and Equipment, gross	5,928		3,379
Equipment [Member] | Maximum [Member]
Estimated Useful Life	7 years
Equipment [Member] | Minimum [Member]
Estimated Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, gross	1,545		487
Furniture and Fixtures [Member] | Maximum [Member]
Estimated Useful Life	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Estimated Useful Life	5 years
Manufacturing Equipment [Member]
Property, Plant and Equipment, gross	13,101		$8,098
Manufacturing Equipment [Member] | Maximum [Member]
Estimated Useful Life	10 years
Manufacturing Equipment [Member] | Minimum [Member]
Estimated Useful Life	5 years
[1]	The estimated useful life of the leasehold improvements is the lesser of the lease term or the estimated useful life.

Note_7_Debt_Details_Textual

Note 7 - Debt (Details Textual) (Revolving Credit Facility [Member], Bank of America NA [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
Revolving Credit Facility [Member] | Bank of America NA [Member]
Debt Disclosure [Abstract]
Long-term Line of Credit		$0
Line of Credit Facility, Maximum Borrowing Capacity	$15,000,000

Note_8_Commitments_and_Conting2

Note 8 - Commitments and Contingencies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	5-May-10
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, Rent Expense, Net	$1,698,000	$498,000
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Neopharm [Member]
Commitments and Contingencies Disclosure [Abstract]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$20,000,000
Business Acquisition, Share Price			$0.70

Note_8_Commitments_and_Conting3

Note 8 - Commitments and Contingencies - Future Minimum Commitments for Operating Leases (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Years ending December 31,
2015	$1,896
2016	2,062
2017	1,989
2018	1,770
2019	1,795
Thereafter	5,160
Total	$14,672

Note_9_Equity_Details_Textual

Note 9 - Equity (Details Textual) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended
	7-May-13	Feb. 26, 2014	Dec. 31, 2013	Aug. 31, 2014	Dec. 31, 2014	6-May-14	5-May-14	Nov. 08, 2010
Stockholders' Equity Note [Abstract]
Preferred Stock, Par or Stated Value Per Share			0.001		$0.00
Common Stock, Par or Stated Value Per Share			0.01	$0.01	$0.01	$0.01
Stock Issued during Period Per Share, Stock Split		1
Common Stock, Shares Authorized			50,000,000		100,000,000	100,000,000	50,000,000
Stock Issued During Period, Shares, New Issues	6,900,000
Share Price	$5.33
Proceeds from Issuance Initial Public Offering	$32,500,000
Underwriting Discounts and Commissions for Public Offering	2,600,000
Offering Expenses for Public Offering	1,800,000
Pre-split Basis [Member]
Stockholders' Equity Note [Abstract]
Common Stock, Par or Stated Value Per Share		0.0002145
Stock Issued During Period, Shares, New Issues	4,600,000
Share Price	$8
Convertible Preferred Stock [Member]
Stockholders' Equity Note [Abstract]
Stock Issued During Period, Shares, Conversion of Convertible Securities	12,793,290		-14,864,607
Convertible Preferred Stock [Member] | Pre-split Basis [Member]
Stockholders' Equity Note [Abstract]
Stock Issued During Period, Shares, Conversion of Convertible Securities	8,528,860
Kapoor Notes [Member]
Stockholders' Equity Note [Abstract]
Stock Issued During Period, Shares, Conversion of Convertible Securities	11,115,512
Debt Conversion, Original Debt, Amount	$59,284,000
Kapoor Notes [Member] | Pre-split Basis [Member]
Stockholders' Equity Note [Abstract]
Stock Issued During Period, Shares, Conversion of Convertible Securities	7,410,341
Series A Preferred Stock [Member]
Stockholders' Equity Note [Abstract]
Preferred Stock, Par or Stated Value Per Share				$0.00
Preferred Stock Purchase Price				160
Minimum Ownership Percentage Acquired to Trigger Preferred Stock Purchase Rights				15.00%
Preferred Stock, Dividend Rate, Per-Dollar-Amount				$1
Multiple used to Determine Preferred Stock Dividend				100
Preferred Stock, Liquidation Preference Per Share				$100
Number of Votes for each Preferred Share				100
Stock Split From [Member]
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note, Stock Split, Conversion Ratio		2
Stock Split To [Member]
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note, Stock Split, Conversion Ratio		3
Neopharm [Member]
Stockholders' Equity Note [Abstract]
Convertible Preferred Stock, Shares Issued upon Conversion								0.57377

Note_10_Stockbased_Compensatio2

Note 10 - Stock-based Compensation (Details Textual) (USD $)	12 Months Ended		24 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,853,581	4,497,489	3,853,581	3,258,860
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost	$4,016,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	34,118,000		34,118,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years
Proceeds from Stock Options Exercised	8,956,000	2,102,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$22,003,000	$2,745,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$21.05	$10.07
Amended and Restated Equity Incentive Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	316,613		316,613
Share-based Compensation Arrangement by Share-based Payment Award, Stock Option Term		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Amended and Restated Equity Incentive Plan [Member] | Non Employee Consultant [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Employee Stock Purchase Plan 2013 [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	262,500		262,500
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Annual Automatic Increase, Percent	1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Additional Annual Shares Automatically Authorized, Period Increase, Option Shares	300,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans			546,112
Employee Stock Purchase Plan 2013 [Member] | Pre-split Basis [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	175,000		175,000
Share-based Compensation Arrangement by Share-based Payment Award, Additional Annual Shares Automatically Authorized, Period Increase, Option Shares	200,000
Equity Incentive Plan Twenty Thirteen [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	197,225		197,225
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Annual Automatic Increase, Percent	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,808,111		2,808,111
Two Thousand Six Equity Incentive Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	728,857		728,857
Share-based Compensation Arrangement by Share-based Payment Award, Stock Option Term	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Two Thousand Six Equity Incentive Plan [Member] | Non Employee Directors [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year

Note_10_Stockbased_Compensatio3

Note 10 - Stock-based Compensation - Stock-Based Compensation Expense (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Allocated share-based compensation expense	$15,289	$6,339
General and Administrative Expense [Member]
Allocated share-based compensation expense	9,791	5,424
Research and Development Expense [Member]
Allocated share-based compensation expense	$5,498	$915

Note_10_Stockbased_Compensatio4

Note 10 - Stock-based Compensation - Stock Option Activity (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Outstanding as of December 31, 2012 (in shares)	3,853,581	4,497,489	3,258,860
Outstanding as of December 31, 2012 (in dollars per share)	$15.14	$5.79	$2.12
Granted (in shares)	1,698,599	2,230,050
Granted (in dollars per share)	$29.13	$9.71
Cancelled (in shares)	-534,112	-87,444
Cancelled (in dollars per share)	$15.42	$5.71
Exercised (in shares)	-1,808,395	-903,977
Exercised (in dollars per share)	$4.95	$2.31
Outstanding as of December 31, 2014	8 years 109 days
Outstanding as of December 31, 2014	$104.10
Vested and exercisable as of December 31, 2013 (in shares)	1,330,360	1,810,653
Vested and exercisable as of December 31, 2013 (in dollars per share)	$7.90	$2.80
Vested and exercisable as of December 31, 2013	7 years 73 days	7 years 18 days
Vested and exercisable as of December 31, 2013	$45.60	$41.70

Note_10_Stockbased_Compensatio5

Note 10 - Stock-based Compensation - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Expected volatility	69.30%	73.54%
Risk-free interest rate	1.72%	2.04%
Expected term (in years)	6 years	7 years
Expected dividend yield	0.00%	0.00%

Note_11_Income_Taxes_Details_T

Note 11 - Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$0
Deferred Tax Assets, Valuation Allowance	20,402,000	20,684,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%
Effective Income Tax Rate Reconciliation, Percent	40.80%	-27.90%
Unrecognized Tax Benefits	5,366,000	325,000
Other Permanent Differences [Member]
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits	1,257,000
State and Local Income Tax Filing Positions [Member]
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits	2,503,000
Tax Credits [Member]
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits	1,606,000
Domestic Tax Authority [Member]
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	1,600,000
State and Local Jurisdiction [Member]
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	272,000,000
State and Local Jurisdiction [Member] | Illinois [Member]
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	269,500,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local, Not Utilized	263,200,000
Deferred Tax Assets, Valuation Allowance	$20,400,000

Note_11_Income_Taxes_Income_Ta

Note 11 - Income Taxes - Income Tax (Benefit) Expense (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current income taxes:
Federal	$22,500	$2,281
State and local	3,874	957
Total current income tax	26,374	3,238
Deferred income taxes:
Federal	867	-9,123
State and local	-1,042	-2,915
Total deferred income tax	-175	-12,038
Provision (benefit) for income taxes	$26,199	($8,800)

Note_11_Income_Taxes_Deferred_

Note 11 - Income Taxes - Deferred Tax Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
NOLs and credits	$24,683	$23,429
Start-up expenditures	3,349	3,613
Stock-based compensation	4,351	2,411
Deferred revenue and allowances	2,516	2,310
Expenses currently not deductible for tax purposes	3,884	2,116
Other	149
Gross deferred tax assets	38,932	33,879
Deferred tax asset valuation allowance	-20,402	-20,684
Deferred tax assets	18,530	13,195
Deferred tax liabilities:
Federal impact of state taxes	-1,384	-1,021
Property and equipment	-4,354	-136
Prepaid expenses	-579
Net deferred tax assets	$12,213	$12,038

Note_11_Income_Taxes_Effective

Note 11 - Income Taxes - Effective Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
U.S. statutory tax rate	35.00%	35.00%
Increase (reduction) of income taxes resulting from:
State income taxes, net of federal benefit	2.90%	11.80%
Non-deductible litigation expense	3.00%
Other non-deductible and includible items and credits	0.60%	2.30%
Research and other credits	-2.20%	-1.80%
Uncertain tax positions	1.80%
Other	-0.30%	-0.60%
Change in valuation allowance	0.00%	-74.60%
Total (benefit) provision for income taxes	40.80%	-27.90%

Note_11_Income_Taxes_Beginning

Note 11 - Income Taxes - Beginning and Ending Amounts of Unrecognized Tax Benefits (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Beginning balance	$325,000
Additions based on current year tax positions	450,000	270,000
Additions based on prior year tax positions	4,591,000	55,000
Ending balance	$5,366,000	$325,000

Note_12_Net_Income_Per_Share_D

Note 12 - Net Income Per Share (Details Textual)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0
Equity Option [Member]
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		890,186

Note_12_Net_Income_Per_Share_C

Note 12 - Net Income Per Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Historical net income per share - Basic
Net Income (Loss) Attributable to Parent	$37,977	$40,377
Weighted average number of common shares outstanding (in shares)	34,379,535	25,919,768
Basic net income per common share (in dollars per share)	$1.10	$1.56
Historical net income per share - Diluted
Net Income (Loss) Attributable to Parent	$37,977	$40,377
Weighted average number of common shares outstanding (in shares)	34,379,535	25,919,768
Effect of dilutive stock options (in shares)	2,288,031	2,814,849
Weighted average number of common shares outstanding (in shares)	36,667,566	28,734,617
Diluted net income per common share (in dollars per share)	$1.04	$1.41

Note_13_Product_Lines_Concentr2

Note 13 - Product Lines, Concentration of Credit Risk and Significant Customers (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Risks and Uncertainties [Abstract]
Number of Product Lines	2
Concentration Risk, Percentage	100.00%	100.00%
Cash, FDIC Insured Amount	$250,000
Accounts Receivable [Member] | Pharmaceutical Wholesalers [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Number of Customers	4	4
Accounts Receivable [Member] | Pharmaceutical Wholesalers [Member] | Customer Four [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	14.00%	14.00%
Accounts Receivable [Member] | Pharmaceutical Wholesalers [Member] | Customer One [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	26.00%	40.00%
Accounts Receivable [Member] | Pharmaceutical Wholesalers [Member] | Customer Three [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	23.00%	17.00%
Accounts Receivable [Member] | Pharmaceutical Wholesalers [Member] | Customer Two [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	24.00%	21.00%
Product Shipments [Member] | Pharmaceutical Wholesalers [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Number of Customers	4	4
Product Shipments [Member] | Pharmaceutical Wholesalers [Member] | Customer Four [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	14.00%	19.00%
Product Shipments [Member] | Pharmaceutical Wholesalers [Member] | Customer One [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	38.00%	30.00%
Product Shipments [Member] | Pharmaceutical Wholesalers [Member] | Customer Three [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	14.00%	20.00%
Product Shipments [Member] | Pharmaceutical Wholesalers [Member] | Customer Two [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	22.00%	21.00%

Note_13_Product_Lines_Concentr3

Note 13 - Product Lines, Concentration of Credit Risk and Significant Customers - Summary of Net Revenue by Product Line and Percentages (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenues	$222,125	$99,289
Dronabinol Sg Capsule [Member]
Revenues	2,595	3,549
Subsys [Member]
Revenues	$219,530	$95,740

Note_13_Product_Lines_Concentr4

Note 13 - Product Lines, Concentration of Credit Risk and Significant Customers - Percentage of Revenue by Route to Market (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Concentration Risk Percentage	100.00%	100.00%
Sales Revenue, Goods, Net [Member] | Product Concentration Risk [Member] | Generic Pharmaceutical Distributor [Member]
Concentration Risk Percentage	1.00%	4.00%
Sales Revenue, Goods, Net [Member] | Product Concentration Risk [Member] | Pharmaceutical Wholesalers [Member]
Concentration Risk Percentage	99.00%	96.00%

Note_14_Supplemental_Financial2

Note 14 - Supplemental Financial Information - Allowances for Accounts Receivables (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts [Member]
Balance at Beginning of Year	$0	$0
Charged to Costs and Expenses	398,000	0
Utilization	0	0
Balance at End of Year	398,000	0
Allowance for Sales Wholesaler Discountss Prompt Pay Discountss Stocking Allowancess and Chargebacks [Member]
Balance at Beginning of Year	2,748,000	834,000
Charged to Costs and Expenses	22,395,000	8,512,000
Utilization	-19,725,000	-6,598,000
Balance at End of Year	$5,418,000	$2,748,000